Orgenesis

Orgenesis operates a decentralized manufacturing and commercialization platform for personalized cell and gene therapies. Under the POCare Platform, the company sources early-stage therapy assets, packages them with proprietary automated processing technology housed in mobile units called OMPULs, and connects to a network of hospitals and research institutions. The goal is to shorten the time and cut the cost required to bring CGTs to market by manufacturing them at or near the point of care rather than at a distant, centralized facility.

The company identifies early-stage biotechnology developers and partners with academic research institutes and hospitals. Under the POCare Therapies component, Orgenesis brings development and validation of selected assets in-house. The POCare Technologies arm then works with third-party technology providers to build the automated processing systems that are validated for use inside the OMPUL units and across the network.

POCare Centers serve as the regional manufacturing and service hubs within the network. OMPUL mobile units are deployed inside or adjacent to these centers and to local hospitals. The center manages quality assurance, data, and supply chain across the connected OMPULs, enabling a distributed but centrally harmonized manufacturing footprint. As demand grows, additional OMPULs can be linked to the same center.